COVID-19 Nucleocapsid Protein mRNA-LNP

The spike protein of COVID-19 is a glycoprotein that helps the virus attach to various surfaces in the built environment, increasing the potential for virus transmission. The best-known vaccines we use are the spike protein vaccines delivered via mRNA. While the role of vaccination in controlling outbreaks is undeniable, the recurring emergence of new variants of Covid-19, such as the Delta and Omicron variants, poses new challenges, particularly their rapid global spread. It is thought that the development of a COVID-19 nucleocapsid (N) protein vaccine may prevent the re-emergence of Covid-19 due to its new variants. The N protein is a protein that packages the positive-sense RNA genome of coronaviruses to form a ribonucleoprotein structure enclosed within the viral capsid. The N protein is the most highly expressed of the four major coronavirus structural proteins. In addition to interacting with RNA, N also forms protein-protein interactions with coronavirus membrane proteins during virus assembly. The N protein is highly immunogenic, and N antibodies were found in recovered COVID-19 patients. This product is designed as a tool for the delivery and expression of full-length nucleocapsid protein mRNA for vaccine research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of the COVID-19 nucleocapsid protein mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The nucleocapsid protein sequence consists of 419 amino acids, and GenPept accession number is YP_009724397. The full-length amino acid sequence of this Nucleocapsid mRNA-LNP product is available upon request.